A weight-loss drug turned up somewhere unexpected: the lungs
Semaglutide is known for two jobs. As Ozempic it treats type 2 diabetes, and as Wegovy it drives weight loss. A large study of UK health records now suggests it may quietly be doing a third one that nobody prescribed it for: keeping asthma attacks at bay.
Presented at the European Respiratory Society Congress in Barcelona in September 2026, the analysis found that people with asthma who started semaglutide had nearly 40 percent fewer asthma attacks than similar patients put on an older diabetes drug. Flare-ups of chronic obstructive pulmonary disease, or COPD, fell by about 20 percent. It is an encouraging, and genuinely surprising, result. It also comes with a fine print that most headlines skipped, and the fine print is worth reading.
| Finding | Plain-English meaning |
|---|---|
| Nearly 40% fewer asthma attacks with semaglutide | A large drop, but from health records, not a controlled trial. |
| About 20% fewer COPD flare-ups | A smaller, less certain benefit that sat at the edge of significance. |
| Only semaglutide showed it, not the other GLP-1 drugs | Liraglutide, dulaglutide and exenatide were not linked to fewer attacks. |
| Four studies of 20,000 to 22,000 people each | A big real-world sample, compared against an older diabetes pill. |
| It is an association, not proof | Shows the two travel together, not that the drug caused it. |
What the researchers actually did
The team, led by Professor Chloe Bloom of the National Heart and Lung Institute at Imperial College London, did not run a new trial. They mined existing UK electronic medical records, which is faster and cheaper but comes with trade-offs we will get to.
They set up four parallel comparisons, each with roughly 20,000 to 22,000 people. In every one, they compared patients who started a GLP-1 drug against patients who started a sulfonylurea, an older and cheaper diabetes medication. The point of that head-to-head design is fairness: both groups were sick enough to need diabetes treatment, so the comparison is not simply healthy people against unhealthy ones.
To tighten it further, the researchers used a statistical method that adjusts for the things that could muddy the picture: body weight, smoking, a marker of allergic inflammation called eosinophils, how severe someone’s airway disease was, and other illnesses. The goal was to compare like with like as closely as records allow.
The number most coverage skipped
The clean headline is “nearly 40 percent fewer asthma attacks.” True, but it flattens the most interesting finding.
The benefit was not shared across the drug class. Among all the GLP-1 medications the team examined, only semaglutide, the molecule in Ozempic and Wegovy, was tied to fewer airway attacks. Liraglutide, dulaglutide and exenatide, three other widely used GLP-1 drugs, showed no such link. In the researchers’ own framing, that points to differences within the class rather than a blanket effect of GLP-1 drugs on the lungs.
For people with asthma, the association was strong: semaglutide users had roughly one fifth the odds of an attack that the comparison group had, in the statistical models. The COPD result was real but weaker and shakier, landing right at the boundary where a finding could still be down to chance. So the honest reading is: a strong asthma signal, a softer COPD one, and a benefit that seems specific to one drug.
Why a metabolic drug might touch the lungs
It sounds odd for a diabetes and weight drug to affect breathing. The likely explanation is inflammation.
Obesity and metabolic dysfunction are common in people with asthma and COPD, and they tend to make attacks more frequent and more severe. Dr. Alexander Mathioudakis of the University of Manchester, a respiratory specialist who was not part of the study, called metabolic health an under-recognized problem in airway disease. GLP-1 drugs lower weight and blood sugar, but growing evidence suggests they also calm inflammation in ways that reach beyond the waistline. Any of those threads, or all of them together, could plausibly ease airway attacks. This study cannot say which, and that is a real limit rather than a footnote.
The honest gaps
A few things need to stay in view before this becomes “asthma inhaler in a pen.”
- It is not peer-reviewed yet. This was presented at a conference, not published in a journal, so it has not been through the full scrutiny that comes later.
- It is observational. Real-world records can show that semaglutide use and fewer asthma attacks appeared together, but they cannot prove the drug caused the drop. Something the records did not capture, a difference between the kinds of patients who end up on semaglutide, could explain part of the gap.
- The COPD result is borderline. It sat right at the edge of statistical significance, so it should be treated as a hint, not a conclusion.
- It is one country, one dataset. A single UK records analysis needs to be repeated elsewhere before anyone leans on it.
The researchers are clear about the way forward: a proper clinical trial that includes asthma attacks and COPD flare-ups as outcomes it measures on purpose, rather than benefits spotted after the fact.
What to do with this if you have asthma or COPD
The useful response is interest, not action at the pharmacy counter.
- Do not start a GLP-1 drug for your lungs. The people who ran the study said so directly. This is not a reason to seek semaglutide outside the normal rules for diabetes or obesity.
- If you already qualify for semaglutide, mention your asthma. For someone with type 2 diabetes or obesity who also has airway disease, this is a reason to have an informed conversation with a clinician, not to self-prescribe.
- Do not stop your inhalers or controller medicine. Nothing here replaces standard asthma or COPD treatment. This is a possible bonus, not a substitute.
- Watch for the trial. The finding that matters will be a controlled study built to test this on purpose. Until then, treat the 40 percent as a promising signal, not a proven treatment.
The real significance is not that asthma has a new drug, because it does not, at least not yet. It is that a medicine millions already take for other reasons may be doing more than its label claims, and that one drug in the class stood out while the others did not. That is exactly the kind of clue that sends researchers back to the lab to find out why.
Related Coverage
- Women on GLP-1 drugs had about 30 percent lower odds of breast cancer
- GLP-1 medications linked to a 17 percent drop in long-term sick leave
Sources:
- sciencedaily.com, “Ozempic and Wegovy linked to nearly 40% fewer asthma attacks” (https://www.sciencedaily.com/releases/2026/09/260909005155.htm)
- hcplive.com, “Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study” (https://www.hcplive.com/view/semaglutide-cuts-asthma-attacks-by-up-to-40-real-world-study)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.